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A B S T R A C T   
Purpose: To analyze the predictive value of ΔT1 of the liver and spleen as well as the extracellular volume fraction 
(ECV) of the spleen as noninvasive biomarkers for the determination of clinically significant portal hypertension 
(CSPH) on routine Gd-EOB-DTPA liver MRI. 
Method: 195 consecutive patients with known or suspected chronic liver disease from 9/2018 to 7/2019 with Gd- 
EOB-DTPA liver MRI and abdominal T1 mapping were retrospectively included. Based on the presence of 
splenomegaly with thrombocytopenia, ascites and portosystemic collaterals, the patients were divided into 
noCSPH (n = 113), compensated CSPH (cCSPH, ≥1 finding without ascites; n = 55) and decompensated CSPH 
(dCSPH, ascites ± other findings; n = 27). T1 times were measured in the liver, spleen and abdominal aorta in the 
unenhanced and contrast-enhanced T1 maps. Native T1 times and ΔT1 of the liver and spleen as well as ECV of 
the spleen were compared between groups using the Kruskal-Wallis test with Dunn’s post hoc test. Furthermore, 
cutoff values for group differentiation were calculated using ROC analysis with Youden’s index. 
Results: ΔT1 of the liver was significantly lower in patients with cCSPH and dCSPH (p < 0.001) compared to 
patients with noCSPH. In the ROC analyses for differentiation between noCSPH and CSPH (cCSPH + dCSPH), a 
cutoff of < 0.67 for ΔT1 of the liver (AUC = 0.79) performed better than ΔT1 (AUC = 0.69) and ECV (AUC =
0.63) of the spleen with cutoffs of > 0.29 and > 41.9, respectively. 
Conclusion: ΔT1 of the liver and spleen in addition to ECV of the spleen allow for determination of CSPH on 
routine Gd-EOB-DTPA liver MRI.   
Abbreviations and acronyms: ALT, Alanine aminotransferase; AP, Alkaline phosphatase; APRI, Aminotransferase to platelet ratio index; ARLD, Alcohol-related 
liver disease; ASH, Alcoholic steatohepatitis; AST, Aspartate aminotransferase; AUROC, Area under the receiver operating characteristic curve; BMI, Body mass 
index; cCSPH, Compensated clinically significant portal hypertension; CLD, Chronic liver disease; CSPH, Clinically significant portal hypertension; dCSPH, 
Decompensated clinically significant portal hypertension; DWI, Diffusion-weighted imaging; ECV, Extracellular volume fraction; FIB-4, Fibrosis-4 index; FS, Fat- 
saturated; Gd-EOB-DTPA, Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid; GGT, Gamma-glutamyl transpeptidase; HASTE, Half-Fourier acquisition 
single-shot turbo spin echo; HVPG, Hepatic venous pressure gradient; LSN, Liver surface nodularity; MIP, Maximum intensity projection; MRE, Magnetic resonance 
elastography; NAFLD, Nonalcoholic fatty liver disease; NASH, Nonalcoholic steatohepatitis; NPV, Negative predictive value; OATP, Organic anion transporting 
polypeptide; PBC, Primary biliary cholangitis; PPV, Positive predictive value; PSC, Primary sclerosing cholangitis; shMOLLI, Shortened modified look-locker 
inversion recovery; TIPS, Trans-jugular intrahepatic portosystemic shunt; VIBE, Volumetric interpolated breath-hold examination. 
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1. Introduction 
Patients with chronic liver disease (CLD) and, in particular, cirrhosis 
have a high risk of developing clinically significant portal hypertension 
(CSPH) [1,2]. CSPH is associated with potentially fatal complications, 
such as variceal hemorrhage, ascites, hepatic encephalopathy, renal 
dysfunction, and adverse outcomes after liver surgery and transarterial 
chemoembolization [2–6]. Currently, liver cirrhosis is the fourth leading 
cause of death in the adult population of Central Europe and is 
responsible for approximately 170,000 deaths annually in Europe, and 
the majority of deaths are not due to hepatocyte failure but instead are 
due to complications associated with CSPH [7,8]. Noninvasive imaging 
biomarkers may allow for determining the presence or absence of CSPH 
for a better characterization of CLD and outcome prediction before 
planned liver surgery or endovascular interventions [2,9]. 
Magnetic resonance (MR) biomarkers to determine the presence of 
CSPH are mainly focused on liver segmental volumes, segmental volume 
ratios [10] and spleen size [11] as well as the presence or absence of 
liver surface nodularity [12], ascites and portosystemic collaterals [13]. 
T1 mapping techniques have shown promising results to quantify liver 
fibrosis and to determine the degree of liver inflammation in CLD 
[14,15]. Another method that has already been studied in the context of 
CSPH is MR elastography (MRE). MRE allows a noninvasive quantitative 
measurement of the hepatic and splenic stiffness [16], which may 
represent a helpful biomarker for the characterization of patients with 
CSPH, as an increased splenic stiffness is associated with CSPH and 
gastroesophageal varices [17,18]. Recently, the T1 mapping-derived 
extracellular volume fraction (ECV) of the spleen has been shown to 
be able to distinguish between healthy volunteers and patients with 
severe portal hypertension undergoing a transjugular intrahepatic por-
tosystemic shunt (TIPS) procedure [6]. This proof-of-concept study has 
demonstrated that MR T1 mapping techniques have good potential, not 
only when measured in the liver but also in the spleen. However, the 
abovementioned study is limited by the differentiation between healthy 
volunteers and a small group of patients with end-stage liver cirrhosis 
and severe portal hypertension, in which the differences are obvious. 
Validation in a clinical setting with more heterogeneous patients un-
dergoing liver MRI is therefore needed. 
Another possible limitation for the use of ECV in routine clinical liver 
MRI is that ECV calculation is based on the use of MR contrast agents 
with extracellular distribution, while routine clinical liver MRI is 
often performed using hepatocyte-specific contrast agents, such as 
gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB- 
DTPA). Instead of distributing to the extracellular space as an extracel-
lular contrast agent, approximately 50% of circulating Gd-EOB-DTPA is 
actively taken up from hepatic sinusoids into hepatocytes by organic 
anion-transporting polypeptides (OATP1B1 and OATP1B3) [19,20], 
thereby rendering ECV calculation in the liver impossible. Because Gd- 
EOB-DTPA is a paramagnetic substance that shortens the longitudinal 
relaxation (T1) time, ΔT1 of the liver can be calculated as a noninvasive 
imaging biomarker to quantify hepatocellular function. ΔT1 represents 
the difference in the T1 relaxation time before and after Gd-EOB-DTPA 
application in the hepatobiliary phase [19]. 
Because the spleen has no hepatocytes, the remaining 50% of Gd- 
EOB-DTPA without hepatobiliary clearance may act similarly to an 
extracellular agent in the spleen, thereby allowing the calculation of the 
ECV in the spleen. Additionally, calculation of ΔT1 in the spleen may be 
a simplified but robust alternative to the complex ECV evaluation 
without the need to know the patient’s hematocrit as previously shown 
in myocardial and skeletal muscles [21]. Both the ECV and ΔT1 may be 
calculated in the spleen to determine the extent of splenic extracellular 
space using a Gd-EOB-DTPA liver MRI. It has not been previously re-
ported whether ΔT1 of the liver along with ΔT1 and ECV of the spleen 
allow the determination of CSPH using routine clinical Gd-EOB-DTPA 
MRI. 
The present study analyzed the predictive value of ΔT1 of the liver 
Fig. 1. Flowchart of the study population.  
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and spleen and the extracellular volume fraction of the spleen as 
noninvasive biomarkers for the determination of clinically significant 
portal hypertension (CSPH) using routine Gd-EOB-DTPA liver MRI. 
2. Material and methods 
2.1. Study population 
The Institutional Review Board approved this retrospective study. All 
patients gave written informed consent or were informed without 
dissent. We screened 1,432 consecutive abdominal MR examinations 
from our hospital database between September 2018 and July 2019. 
Exams using extracellular contrast agents (n = 806) or no contrast agent 
(n = 77) were excluded. From the resulting 549 dedicated liver MRIs 
with Gd-EOB-DTPA, 101 were excluded due to missing T1 mapping. 
Other MRI exams were excluded for the following reasons: repetitive 
exams on the same patient (n = 89, only the first exam of each patient 
was included); noncirrhotic etiology of portal hypertension (n = 43); 
past surgical intervention involving the liver or the portal venous system 
(n = 36); splenomegaly due to an etiology other than portal hyperten-
sion (n = 18); patients with multiple hepatic lesions (n = 31); technical 
failure of T1 mapping sequences (n = 14); spleen not covered on T1 
mapping sequence (n = 9); and splenic lesions (n = 3). Finally, 10 pa-
tients were excluded due to missing laboratory results or missing patient 
documentation. Thus, the final study population included 195 patients, 
from which 100 patients were examined at 1.5T and 95 patients were 
examined at 3T (Fig. 1). 
2.2. Imaging techniques 
All MRI examinations were performed using a whole-body 1.5 Tesla 
MR system (Magnetom Aera 1.5T, Siemens Healthineers, Erlangen, 
Germany, n = 100) or a whole-body 3 Tesla MR system (Magnetom 
Skyra 3T, Siemens Healthineers, Erlangen, Germany, n = 95). The im-
aging protocols were the same at 1.5T and 3T. The standard Gd-EOB- 
DTPA liver protocol was as follows: a T1 volumetric interpolated 
breath-hold examination (VIBE) DIXON 3 mm transversal acquisition of 
the liver, a half-Fourier single-shot turbo spin-echo (HASTE) sequence 3 
mm transversal and coronal acquisition of the liver; a diffusion-weighted 
imaging (DWI) sequence with b = 0, b = 400 and b = 800 s/mm2 values; 
and T1 VIBE fat-saturated (fs) transversal 3 mm acquisitions before and 
after intravenous contrast administration in arterial, venous, delayed 
and hepatobiliary phases after 10 and 20 min. Apart from the standard 
Gd-EOB-DTPA liver imaging protocol, native axial T1 mapping se-
quences and axial T1 mapping sequences 20 min after intravenous 
administration of 0.25 mmol Gd-EOB-DTPA (Primovist®, Bayer 
Healthcare, Berlin, Germany) per kilogram body weight were per-
formed. Specifications of the sequences used are listed in Table A in the 
appendix. For T1 mapping, shortened modified look-locker inversion 
recovery (shMOLLI) single breath-hold sequences with a 5(1)1(1)1 
protocol were used, and images were acquired during a breath-hold time 
of 7–9 s at end-expiration. The total scan time per T1 mapping sequence 
was less than 2 min before and after the application of the contrast 
agent, resulting in a total additional scan time of less than 4 min per 
patient. The scan duration was the same on 1.5T and 3T. To our 
knowledge, this MR T1 mapping protocol has previously been used to 
determine ΔT1 of the liver but not in the spleen [20]. The parametric T1 
maps were created automatically on the scanner and sent to our picture 
archiving and communication system (PACS IDS7, version 21.2, Sectra 
AB, Linköping, Sweden). 
2.3. Image analysis 
All images were analyzed by a trained doctoral student (D.C.; with 1 
year of experience in liver MRI), and every case was visually controlled 
by two board-certified radiologists (V.C.O. and A.T.H. with 7 and 10 
years of experience in liver MRI) who adapted contours when necessary. 
Sectra Workstation PACS IDS7 (version 21.2, Sectra AB, Linköping, 
Sweden) was used for image analyses. T1 relaxation times of the liver 
and spleen were measured by drawing a region of interest (ROI) 
covering each liver segment and the spleen (Fig. 2, A, B, D and E). An 
average value for the liver was then calculated from the individual 
Fig. 2. Measurements of T1 relaxation time and spleen size. Fig. 2. In images A to C, the assessment of a 36-year-old male patient without chronic liver disease and no 
clinically significant portal hypertension (noCSPH) is shown. In images D to F, the same assessment is shown for a 60-year-old female patient with alcoholic liver 
cirrhosis (Child B) and decompensated clinically significant portal hypertension (dCSPH). In A and D, ROIs are placed in the liver, abdominal aorta and spleen on the 
native T1 map. In B and E, ROIs are placed in the liver, abdominal aorta and spleen on the T1 map 20 min after the administration of Gd-EOB-DTPA. In C and F, 
measurement of the spleen is shown on a T2-weighted half-Fourier acquisition single-shot turbo spin echo (HASTE) sequence. For the 36-year-old patient with 
noCSPH, we calculated a ΔT1 of the liver of 0.75, a ΔT1 of the spleen of 0.23 and an ECV of the spleen of 30.8. For the 60-year-old patient with dCSPH, we calculated 
a ΔT1 of the liver of 0.59, a ΔT1 of the spleen of 0.53 and an ECV of the spleen of 48.2. 
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measurements in the liver. The ROIs were drawn to cover the largest 
possible area of liver parenchyma at the same position in pre- and 
postcontrast T1 maps without including large blood vessels and bile 
ducts. While placing the ROIs, a distance from the organ capsule of at 
least 1 cm was maintained. In addition to the liver parenchyma, the 
blood pool was measured in the abdominal aorta on the same T1 maps in 
the diastolic phase of the cardiac cycle using pulse triggering. ΔT1 of the 
liver and spleen and the ECV of the spleen were calculated as follows 
[6,20]: 
ΔT1 liver =
native T1 liver − postcontrast T1 liver
native T1 liver  
ΔT1 spleen =
native T1 spleen − postcontrast T1 spleen
native T1 spleen   
In addition, the largest diameter of the spleen was measured in the 
longest axial direction on T2-weighted images (Fig. 2, C and F). The 
presence or absence of ascites and portosystemic collaterals, such as a 
recanalized paraumbilical vein, gastroesophageal varices and sple-
norenal collaterals, was determined on T2-weighted images with a 6- 
mm slice thickness and T1 VIBE fat-saturated contrast-enhanced im-
ages in the venous phase with a 3-mm slice thickness (Fig. 3). 
2.4. Patient groups 
Clinical data within a period of three months of the MR examination 
and information on the indication for the MR examination were 
collected from our clinical information system. For patients with liver 
cirrhosis, the Child-Pugh score was calculated. Patients were assigned to 
groups based on the presence or absence of clinically significant portal 
hypertension (CSPH) as defined in the Baveno VI consensus statement 
[22]. CSPH was defined as the presence of at least one of the following 
surrogate findings: 1) splenomegaly on MRI (>12 cm measured in the 
largest diameter) with concurrent thrombocytopenia (<100 × 109 
thrombocytes/L blood); 2) ascites on MRI; and 3) portosystemic collat-
erals on MRI. Patients without any of these surrogate findings were 
classified as having noCSPH. Patients with CSPH without ascites were 
allocated to the compensated CSPH subgroup (cCSPH), and CSPH 
patients with ascites were assigned to the decompensated CSPH sub-
group (dCSPH). 
2.5. Statistical analyses 
All statistical analyses were performed using GraphPad Prism 
(version 9.0.1., GraphPad Software, San Diego, California, USA) and 
IBM SPSS Statistics (version 25.0, IBM Corporation, Armonk, New York, 
USA). The Shapiro-Wilk test that was performed to assess the parameters 
for normal distribution in the groups found that the values were not 
normally distributed; therefore, nonparametric tests were used for all 
analyses. Parameters among noCSPH, cCSPH and dCSPH were 
compared using the Kruskal-Wallis test with Dunn’s multiple compari-
son post hoc test for continuous variables or the χ2-test with a post hoc 
test consisting of a Z-test with Bonferroni correction for categorical 
variables [23]. Possible differences in ΔT1 of the liver, ΔT1 of the spleen 
and ECV of the spleen between the 1.5T and 3T groups were compared 
with a Mann-Whitney U test for all patient groups. Receiver operating 
characteristic (ROC) curve analyses were performed for single parame-
ters (ΔT1 liver, ΔT1 spleen and ECV spleen). Cutoff values were deter-
mined using Youden’s index. A multivariate logistic regression analysis 
was performed for combined parameters (ΔT1 liver + ΔT1 spleen; ΔT1 
liver + ECV spleen) with CSPH as the outcome, and the results were used 
to calculate combined-parameter ROC curves for comparison with the 
single-parameter ROC curves. A p-value of 0.05 or less was defined as 
statistically significant. 
3. Results 
3.1. Indications for MR examination 
The most frequent indication for MR examination in our study 
population was the evaluation of liver lesions (n = 85) followed by 
follow-up examinations in patients with HCC (n = 49) and HCC 
screening in patients with chronic liver disease (n = 18). Moreover, 13 
examinations were performed as follow-up examinations in patients 
with liver metastases, and 6 examinations were performed for the 
evaluation of neuroendocrine tumors. Furthermore, 5 examinations 
were performed to evaluate pancreatic lesions, and 19 examinations 
were performed for other reasons. 
Fig. 3. Examples of observed signs of clinically significant portal hypertension. Fig. 3. Image A shows the recanalized umbilical vein (arrow) and splenomegaly in an 
85-year-old male patient with alcoholic liver cirrhosis (Child C) and decompensated CSPH (dCSPH) visualized with a maximum intensity projection (MIP) recon-
struction on a T1 VIBE fat-saturated sequence in the venous phase during a breath-hold examination. Image B is of a 66-year-old male patient with alcoholic liver 
cirrhosis (Child B) and decompensated CSPH (dCSPH) with gastroesophageal varices (B, arrow) and splenomegaly on a T1 VIBE fat-saturated sequence in the venous 
phase during a breath-hold examination. Image C shows marked ascites of the same 66-year-old patient on a T2-weighted half-Fourier acquisition single-shot turbo 
spin echo (HASTE) sequence. 
ECV spleen = (1 − hematocrit) ×
(1/postcontrast T1 spleen) − (1/native T1 spleen)
(1/postcontrast T1 aorta) − (1/native T1 aorta)
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3.2. Patient characteristics 
The patient characteristics are shown in Table 1. Of the 195 patients, 
113 patients had noCSPH (61 at 1.5T and 52 at 3T), 55 patients had 
cCSPH (26 at 1.5T and 29 at 3T) and 27 patients had dCSPH (13 at 1.5T 
and 14 at 3T). Patients in the CSPH group had more cases of diabetes, 
higher daily alcohol consumption and higher average body mass index 
(BMI) than patients in the noCSPH group. FIB-4 and APRI were higher in 
CSPH than in noCSPH, which agreed with the clinical patient data. In the 
noCSPH group, only 58% of patients had CLD, whereas in the CSPH 
group, all patients were affected by CLD. The most common etiologies 
Table 1 
Patient characteristics.  








Male, n (%) 65 (58%) 35 (64%) 23 (85%)Z  0.028 
Age, years 65 (53–73) 62 (56–67) 68 (63–72) 
**  
0.035 
BMI, kg/m2 26 (23–29) 28 (25–31)* 28 (23–30)  0.035 
Arterial hypertension, n 
(%) 
55 (49%) 27 (49%) 13 (48%)  0.997 
Therapy for portal 
hypertension with 
nonselective 
β-blocker, n (%) 
0 (0%) 24 (44%)Z 14 (52%)Z  <0.001 
Daily alcohol 
consumption, n (%) 
13 (12%) 11 (20%) 12 (44%)Z  <0.001 
Diabetes mellitus, n (%) 27 (24%) 18 (33%) 9 (33%)  0.379      
Chronic liver disease, n 
(%) 
65 (58%) 55 (100%)Z 27 (100%)Z  <0.001 
CLD without cirrhosis, n 46 0 0  
Child A, n 16 38 3  
Child B, n 3 15 16  
Child C, n 0 2 8       
Signs of clinically 
significant portal 
hypertension, n (%) 




0 22 8  
Collaterals, n 0 55 22  
Ascites, n 0 0 27       
Creatinine, μmol/l 72 (63–85) 74 (58–86) 89 (62–135) 
*  
0.045 
Albumin, g/L 37 (34–40) 35 (32–38) 30 (22–35) 
*/**  
<0.001 
Bilirubin, μmol/l 9 (6–14) 15 (10–22)* 17 (13–38)*  <0.001 
AST, U/l 33 (23–53) 42 (34–69)* 46 (35–67)*  <0.001 
ALT, U/l 33 (22–57) 33 (24–50) 29 (23–48)  0.723 
Alkaline phosphatase, 
U/l 









Hematocrit, % 40 (36–43) 39 (35–42) 32 (28–39) 
*/**  
<0.001 
























Values are presented as median with interquartile range (25–75%) or n (%). P- 
values were calculated using the Kruskal-Wallis test with Dunn’s multiple 
comparison post hoc test or χ2-test as appropriate. * = p < 0.05 in Dunn’s 
multiple comparison test with noCSPH; ** = p < 0.05 in Dunn’s multiple 
comparison test with cCSPH. Z = p < 0.05 in post hoc Z-tests with Bonferroni- 
adjusted p-value with noCSPH. Daily alcohol consumption was defined as ≥ 2 
alcoholic beverages per day for men and ≥ 1 alcoholic beverage per day for 
women or the presence of a history of abusive alcohol consumption. Please note 
that patients could have multiple signs of portal hypertension at the same time. 
BMI = Body mass index; CLD = Chronic liver disease; AST = Aspartate 
aminotransferase; ALT = Alanine aminotransferase; GGT = Gamma-glutamyl-
transferase; FIB-4 = Fibrosis-4 index; APRI = Aspartate aminotransferase to 
platelet ratio index; noCSPH = No clinically significant portal hypertension; 
cCSPH = Compensated clinically significant portal hypertension; dCSPH =
Decompensated clinically significant portal hypertension. 
Table 2 
Results for the liver.  
Parameter noCSPH cCSPH dCSPH p- 
value 
1.5T (n = 61) (n = 26) (n = 13)  















<0.001      
3T (n = 52) (n = 29) (n = 14)  















<0.001      
1.5T þ 3T 
pooled 
(n = 113) (n = 55) (n = 27)  







Values are presented as median with interquartile range (25–75%). P-values 
were calculated using the Kruskal-Wallis test with Dunn’s multiple comparison 
post hoc test. * = p < 0.05 on Dunn’s multiple comparison test with noCSPH. 
noCSPH = No clinically significant portal hypertension; cCSPH = Compensated 
clinically significant portal hypertension; dCSPH = Decompensated clinically 
significant portal hypertension. 
Table 3 
Results for the spleen.  
Parameter noCSPH cCSPH dCSPH p- 
value 























0.009      























0.207      
1.5T þ 3T 
pooled 
(n = 113) (n = 55) (n = 27)  














Values are presented as median with interquartile range (25–75%). P-values 
were calculated using the Kruskal-Wallis test with Dunn’s multiple comparison 
post hoc test. * = p < 0.05 on Dunn’s multiple comparison test with noCSPH. 
noCSPH = No clinically significant portal hypertension; cCSPH = Compensated 
clinically significant portal hypertension; dCSPH = Decompensated clinically 
significant portal hypertension; ECV = Extracellular volume fraction. 
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for CLD were NAFLD/NASH (21 in the noCSPH group and 12 in the 
CSPH group), ARLD/ASH (13 in the noCSPH group and 27 in the CSPH 
group), chronic viral hepatitis (14 in the noCSPH group and 12 in the 
CSPH group) and PSC/PBC (6 in the noCSPH group and 4 in the CSPH 
group). Fourteen patients with noCSPH and 6 patients with CSPH had 
other etiologies. 
3.3. Results for the liver 
The native T1 relaxation times of the liver were significantly longer 
in patients with cCSPH and dCSPH than in patients with noCSPH both at 
1.5TT (noCSPH 590 ms, cCSPH 668 ms, p < 0.001; dCSPH 718 ms, p <
0.001) and at 3T (noCSPH 875 ms, cCSPH 1001 ms, p < 0.001; dCSPH 
991 ms, p = 0.011). Furthermore, ΔT1 of the liver was significantly 
lower in patients with cCSPH and dCSPH than in patients with noCSPH 
at 1.5T (noCSPH 0.70, cCSPH 0.61, p = 0.002; dCSPH 0.57, p = 0.003), 
3T (noCSPH 0.74, cCSPH 0.65, p < 0.001; dCSPH 0.54, p < 0.001) and 
in the pooled analysis (noCSPH 0.71, cCSPH 0.62, p < 0.001; dCSPH 
0.54, p < 0.001). Even if there was a tendency of a lower ΔT1 of the liver 
in patients with dCSPH compared to patients with cCSPH, statistical 
significance was not reached (p > 0.999 at 1.5T; p = 0.081 at 3T; and p 
= 0.088 in pooled analysis) (Table 2). 
3.4. Results for the spleen 
The native T1 relaxation times of the spleen were significantly longer 
Table 4 
ROC curve analysis.  
Parameter Cutoff value AUC Sensitivity, % Specificity, % NPV, % PPV, % Youden’s index p-value 
noCSPH vs. CSPH         
ΔT1 liver < 0.67  0.79 74 72 79 66 46  <0.001 
ΔT1 spleen > 0.29  0.69 80 51 78 54 31  <0.001 
ECV spleen > 41.9  0.63 72 54 73 53 26  0.001          
noCSPH vs. cCSPH         
ΔT1 liver < 0.67  0.75 69 72 83 55 41  <0.001 
ΔT1 spleen > 0.28  0.67 84 44 85 42 28  <0.001 
ECV spleen > 41.5  0.60 71 52 79 42 23  0.032                   
noCSPH vs. dCSPH         
ΔT1 liver < 0.64  0.87 81 78 95 47 59  <0.001 
ΔT1 spleen > 0.29  0.74 89 51 95 30 40  <0.001 
ECV spleen > 40.8  0.70 89 48 95 29 37  0.001 
ROC = Receiver operating characteristic; AUC = Area under the curve; NPV = Negative predictive value; PPV = Positive predictive value; noCSPH = No clinically 
significant portal hypertension; CSPH = Clinically significant portal hypertension; cCSPH = Compensated clinically significant portal hypertension; dCSPH =
Decompensated clinically significant portal hypertension; ECV = Extracellular volume fraction. Number of patients in each group: noCSPH (n = 113), CSPH (n = 82), 
cCSPH (n = 55) and dCSPH (n = 27). 
Fig. 4. ROC curves. Fig. 4. Fig. 4 shows the ROC curves for noCSPH vs. CSPH, noCSPH vs. cCSPH and noCSPH vs. dCSPH for ΔT1 of the liver, ΔT1 of the spleen, ECV 
of the spleen, a combination of ΔT1 of the liver + ΔT1 of the spleen and a combination of ΔT1 of the liver + ECV of the spleen. The p-value and the area under the 
curve (AUC) are given for each ROC curve. noCSPH = No clinically significant portal hypertension; cCSPH = Compensated clinically significant portal hypertension; 
dCSPH = Decompensated clinically significant portal hypertension; ECV = Extracellular volume fraction; AUC = Area under the curve. 
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in patients with cCSPH and dCSPH than in patients with noCSPH at 1.5T 
(noCSPH 1094 ms, cCSPH 1137 ms, p = 0.027; dCSPH 1181 ms, p =
0.003) but not at 3T (noCSPH 1346 ms, cCSPH 1383 ms, p = 0.423; 
dCSPH 1345 ms, p = 0.614). Furthermore, pooled ΔT1 of the spleen was 
significantly higher in patients with cCSPH and dCSPH than in patients 
with noCSPH (noCSPH 0.29, cCSPH 0.34, p = 0.003; dCSPH 0.35, p <
0.001). In the pooled analysis, the ECV of the spleen was significantly 
higher in patients with dCSPH than in patients with noCSPH (noCSPH 
41.3, dCSPH 48.9, p = 0.003) but not in patients with cCSPH (46.6, p =
0.112). There was no significant difference in the pooled analysis be-
tween cCSPH and dCSPH for ΔT1 of the spleen (cCSPH 0.34, dCSPH 
0.35, p = 0.688) and the ECV of the spleen (cCSPH 46.6, dCSPH 48.9, p 
= 0.35) (Table 3). 
3.5. Comparison between 1.5T and 3T 
In patients with noCSPH, ΔT1 of the liver was 0.70 (0.62–0.75) at 
1.5T and 0.74 (0.67–0.79) at 3T (p = 0.055). In patients with cCSPH, 
ΔT1 of the liver was 0.61 (0.57–0.67) at 1.5T and 0.65 (0.53–0.69) at 3T 
(p = 0.622). In patients with dCSPH, ΔT1 of the liver was 0.57 
(0.45–0.68) at 1.5T and 0.54 (0.44–0.57) at 3T (p = 0.302). 
In patients with noCSPH, ΔT1 of the spleen was 0.31 (0.25–0.35) at 
1.5T and 0.29 (0.25–0.34) at 3T (p = 0.360), while the ECV of the spleen 
was 39.9 (34.5–46.2) at 1.5T and 44.6 (36.3–51.3) at 3T (p = 0.073). In 
patients with cCSPH, ΔT1 of the spleen was 0.34 (0.31–0.40) at 1.5T and 
0.32 (0.28–0.38) at 3T (p = 0.407), while the ECV of the spleen was 47.4 
(36.9–49.8) at 1.5T and 44.7 (40.8–55.0) at 3T (p = 0.466). In patients 
with dCSPH, ΔT1 of the spleen was 0.38 (0.32–0.42) at 1.5T and 0.35 
(0.30–0.39) at 3T (p = 0.488), while the ECV of the spleen was 48.9 
(42.3–57.1) at 1.5T and 49.2 (41.8–59.5) at 3T (p = 0.867). 
3.6. Results of the ROC curve analyses 
All ROC curve analyses showed significant results. With regard to a 
cutoff value to distinguish between noCSPH and CSPH patients, the best 
performance was observed for ΔT1 of the liver with a cutoff value of <
0.67, which predicted CSPH with a negative predictive value (NPV) of 
79% and a positive predictive value (PPV) of 66% (AUC = 0.79). ΔT1 of 
the liver was also the best parameter for distinguishing between noCSPH 
and cCSPH with a NPV of 83% and a PPV of 55% (AUC = 0.75) when 
using a cutoff value of < 0.67. An even higher performance of ΔT1 of the 
liver was observed when differentiating between noCSPH and dCSPH 
with a NPV of 95% and a PPV of 47% (AUC = 0.87) when using a cutoff 
value of < 0.64 (Table 4). 
When cutoff values for ΔT1 of the liver, ΔT1 of the spleen and ECV of 
the spleen were combined, the AUC was larger (Fig. 4) with a higher 
positive predictive value for CSPH (PPV = 72% for combination of ΔT1 
of the liver < 0.67 and ΔT1 of the spleen > 0.29; PPV = 77% for com-
bination of ΔT1 of the liver < 0.67 and the ECV of the spleen > 41.9), 
cCSPH (PPV = 61% for combination of ΔT1 of the liver < 0.67 and ΔT1 
of the spleen > 0.28; PPV = 66% for combination of ΔT1 of the liver <
0.67 and the ECV of the spleen > 41.5) and dCSPH (PPV = 58% for 
combination ΔT1 of the liver < 0.64 and ΔT1 of the spleen > 0.29; PPV 
= 67% for combination of ΔT1 of the liver < 0.64 and the ECV of the 
spleen > 40.8) (Table 5). The odds ratios of the multiple logistic 
regression analysis are shown in Appendix B. 
4. Discussion 
This is the first study to show that ΔT1 of the liver, ΔT1 of the spleen 
and ECV of the spleen allow for the determination of CSPH using routine 
Gd-EOB-DTPA liver MRI. The best overall performance was achieved by 
combining ΔT1 of the liver and ΔT1 of the spleen, while the highest 
positive predictive value was achieved by combining ΔT1 of the liver 
and the ECV of the spleen. Therefore, multiparametric T1 mapping of 
the liver and spleen is a reliable method to determine the presence of 
clinically significant portal hypertension using routine Gd-EOB-DTPA 
liver MRI. Because T1 mapping sequences are available on any scan-
ner without the need for additional hardware, they are more widely 
available than MRE. With an additional acquisition time of no>4 min, 
clinicians may depict patients with CLD and portal hypertension earlier 
using routine Gd-EOB-DTPA liver MRI in the future, allowing better risk 
stratification and earlier initiation of treatment for the prevention of 
complications. 
In the liver, there was a tendency for a lower ΔT1 in patients with 
dCSPH than in patients with cCSPH, but statistical significance was not 
reached. Of note, the ECV of the liver could not be evaluated due to the 
use of Gd-EOB-DTPA. The present study did not investigate whether a 
lower ΔT1 of the liver might be explained by a decrease in hepatocel-
lular function in decompensated patients, thereby further studies that 
include more patients with dCSPH are warranted. In the spleen, there 
was no significant difference between ΔT1 and ECV between cCSPH 
Table 5 
Combined ROC curve analysis.  
Parameter AUC Sensitivity, % Specificity, % NPV, % PPV, % p-value 
noCSPH vs. CSPH       
ΔT1 liver (<0.67) + ΔT1 spleen (>0.29)  0.83 61 83 75 72  <0.001 
ΔT1 liver (<0.67) + ECV spleen (>41.9)  0.79 54 88 73 77  <0.001        
noCSPH vs. cCSPH       
ΔT1 liver (<0.67) + ΔT1 spleen (>0.28)  0.79 56 82 79 61  <0.001 
ΔT1 liver (<0.67) + ECV spleen (>41.5)  0.75 49 88 78 66  <0.001        
noCSPH vs. dCSPH       
ΔT1 liver (<0.64) + ΔT1 spleen (>0.29)  0.90 70 88 93 58  <0.001 
ΔT1 liver (<0.64) + ECV spleen (>40.8)  0.87 74 91 94 67  <0.001 
Values were calculated based on a logistic regression analysis with a classification cutoff of 0.5. 
ROC = Receiver operating characteristic; AUC = Area under the curve; NPV = Negative predictive value; PPV = Positive predictive value; noCSPH = No clinically 
significant portal hypertension; CSPH = Clinically significant portal hypertension; cCSPH = Compensated clinically significant portal hypertension; dCSPH =
Decompensated clinically significant portal hypertension; ECV = Extracellular volume fraction. Number of patients in each group: noCSPH (n = 113), CSPH (n = 82), 
cCSPH (n = 55) and dCSPH (n = 27). 
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patients and dCSPH patients. We hypothesized that a lower ΔT1 of the 
liver reflects decreased hepatocellular function, which is directly linked 
to the occurrence of compensated and decompensated CSPH. In addi-
tion, we also hypothesized that a higher ΔT1 and ECV of the spleen 
directly measure the extension of the splenic extracellular space due to 
CSPH, which is unrelated to whether the patents are compensated or 
decompensated. However, these hypotheses should be investigated in 
future studies. 
Our results agreed with recent publications. ΔT1 of the liver is 
known to be significantly reduced in patients with CLD, and it correlates 
with liver function on Gd-EOB-DTPA liver MRI [24,25]. Ding et al. 
showed that ΔT1 of the liver is lower in patients with significant liver 
fibrosis (mean ΔT1 = 0.66 for fibrosis grade 3–4) than in patients 
without significant liver fibrosis (mean ΔT1 = 0.71 for fibrosis grade 
0–2) at 1.5T [26]. The values in patients without significant liver fibrosis 
from the study of Ding et al. are comparable to the ΔT1 values observed 
in noCSPH patients in our study. In cCSPH and dCSPH patients, ΔT1 was 
lower, thus reflecting the decreased function of hepatocytes in these 
patients. 
Studies analyzing T1 mapping of the spleen are sparse. A recent 
publication has shown a longer T1 relaxation time of the spleen at 3T in 
patients with significantly elevated liver stiffness on MR elastography 
[27], which was in accordance with the present study. Another study has 
shown increased ECV of the spleen in patients with end-stage liver 
cirrhosis and severe portal hypertension undergoing a TIPS procedure 
[6], which agreed with our study, showing a significantly higher ECV of 
the spleen in CSPH patients than in noCSPH patients. However, the 
absolute ECV values of the spleen were slightly lower in the study 
by Mesropyan et al. in both groups, which may be related to differences 
between the sequences used and MR scanners from different vendors as 
well as different contrast agents. Mesropyan et al. used gadobutrol, 
which is an extracellular contrast agent, while Gd-EOB-DTPA, which 
was used in the present study, is a hepatocyte-specific contrast agent 
with only one part of the administered Gd-EOB-DTPA distributed to the 
extracellular space of the spleen. In addition, gadobutrol has a different 
relaxivity than Gd-EOB-DTPA [28], and the timing to measure the ECV 
of the spleen differed between the two studies (10 min after gadobutrol 
injection vs. 20 min after Gd-EOB-DTPA injection). Even if gadobutrol is 
more suitable for ECV calculation in the spleen, Gd-EOB-DTPA is more 
widely used for liver MRI in routine clinical practice. Finally, the use of 
gadobutrol allows the calculation of splenic ECV but not in combination 
with ΔT1 of the liver to determine liver function. 
Apart from MRI T1 mapping, there have been other noninvasive MRI 
techniques to assess portal hypertension [29]. For instance, liver stiff-
ness values measured by MRE correlate significantly with the hepatic 
venous pressure gradient (HVPG) and allow for the detection of patients 
with clinically significant portal hypertension with an AUROC of 0.74, a 
sensitivity of 55% and a specificity of 91% [30]. Interestingly, this 
performance was similar to the combined prediction of ΔT1 and ECV of 
the liver and spleen in the present study. MRE measures the increased 
tissue stiffness of the liver and spleen due to liver fibrosis and CSPH, 
while ΔT1 and ECV measure the expansion of the extracellular space of 
the spleen due to CSPH. Therefore, it might be interesting to combine 
ΔT1 and ECV of the liver and spleen with MRE in an upcoming study to 
analyze whether a combination of both methods may incrementally 
increase the predictive value to determine CSPH. Computed tomography 
studies have used the liver surface nodularity (LSN) score to detect pa-
tients with clinically significant portal hypertension [31]. LSN has been 
successfully applied to liver MRI to detect advanced liver fibrosis [32], 
and it has also been shown to correlate with the degree of portal hy-
pertension [12]. It would therefore be interesting to combine ΔT1 of the 
liver, ΔT1 of the and spleen and ECV of the spleen with MRE and the 
MRI-derived LSN score to determine the presence and severity of CSPH 
in patients undergoing routine Gd-EOB-DTPA liver MRI. 
The present study had several limitations. First, this was a retro-
spective study with a heterogeneous patient population. However, due 
to stringent inclusion and exclusion criteria, major confounding factors 
were minimized, and the study population was well characterized. 
Another potential limitation was that our study was conducted using 
both 1.5T and 3T scanners. Due to the measurement of a ratio with 
relative T1 shortening of the spleen, however, there should not be a large 
difference between different field strengths as this has been shown for 
the ECV in other tissue types, such as the myocardium, and for ΔT1 of 
the liver with similar values at 1.5T and 3T [33]. A subanalysis in our 
patient population showed no significant difference between the 
different field strengths. Nevertheless, the results of the present study 
should be validated in further prospective studies. Finally, there were no 
invasive measurements of the hepatic venous pressure gradient, which 
was not possible due to ethical considerations in this patient population. 
However, the presented clinical approach to determine CSPH allowed us 
to investigate a large cross-sectional study in a realistic setting of pa-
tients in a radiology department undergoing liver MRI with Gd-EOB- 
DTPA. 
5. Conclusions 
In conclusion, ΔT1 of the liver, ΔT1 of the and spleen and ECV of the 
spleen allow for the determination of CSPH using routine Gd-EOB-DTPA 
liver MRI in a clinical setting. Consequently, ΔT1 of the liver and spleen 
as well as the ECV of the spleen may be helpful imaging biomarkers to 
characterize patients with CLD more accurately to allow both improved 
risk stratification and better individualized therapy of CSPH without 
relying on invasive portal venous pressure measurement. 
When using ΔT1 of the liver, ΔT1 of the and spleen and ECV of the 
spleen to detect CSPH, a combination of both decreased ΔT1 of the liver 
and increased ΔT1 and ECV of the spleen may perform better than ΔT1 
of the liver alone as this combination showed a notably higher positive 
predictive value for CSPH in our study. However, whether this combi-
nation of parameters is also associated with adverse outcomes warrants 
further investigation.  
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